Stabilized Enveloped Viruses by Spray-Drying and Lyophilization

The USPTO published patent application US20260091106A1 on April 2, 2026, disclosing compositions and methods for making thermostable enveloped viruses using spray-drying and lyophilization techniques. The inventions aim to reduce degradation, preserve virus activity and titer, and prolong storage stability for transport and later use. Application 19348562 was filed October 2, 2025 by inventors Coleman, Randolph, Schwartz, and Garcea.

RSV vaccine method, single dose, stronger immunity

The USPTO published patent application US20260091105A1 by inventors Peter L. Collins and Ursula J. Buchholz covering a method of vaccination using a single dose of a recombinant RSV lacking the M2-2 protein. The vaccine reportedly induces a stronger immune response than previous candidates despite being more restricted in replication. The application (No. 18898953) was filed September 27, 2024.

Nucleic Acid Vaccine Patent Application

USPTO published patent application US20260091104A1 filed by ModernaTX, Inc. for nucleic acid vaccine compositions and methods. The application (No. 19188713) covers ribonucleic acid vaccines encoding antigens, filed on April 24, 2025, and lists three inventors: Giuseppe Ciaramella, Axel Bouchon, and Eric Yi-Chun Huang.

CureVac SE Bunyavirales vaccine patent application

CureVac SE Bunyavirales vaccine patent application

Hydrochloric acid salt of 5-HT2C agonist patent application

USPTO published patent application US20260091039A1 for a crystalline hydrochloric acid salt of (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (a 5-HT2C agonist). The application includes pharmaceutical composition claims and methods of use. Inventor: Anthony Clyde Blackburn. Application No. 19344622.

Ligand-Enabled Scalable C-H Hydroxylation of Benzoic and Phenylacetic Acids at Room Temperature

The USPTO published patent application US20260092029A1 by Yu/Quan et al. disclosing methods for Pd-catalyzed C-H hydroxylation of benzoic and phenylacetic acids at room temperature using bifunctional pyridone-carboxylic acid ligands and aqueous hydrogen peroxide as oxidant. The application, filed September 7, 2023, also covers synthesis of polyfluorinated natural products and ibuprofen hydroxylation.

Heterocyclic Compound Orexin 2 Receptor Agonist Narcolepsy Treatment

The USPTO published patent application US20260092033A1 for a heterocyclic compound as an orexin 2 receptor agonist for treating narcolepsy. Inventors include researchers from a Japanese pharmaceutical company. The application claims priority to Application No. 19287436 filed July 31, 2025. This is a standard pharmaceutical patent filing that does not impose regulatory obligations on third parties.

7-Azaindole Analogs and Serotonin Agonists for Neurological Disorders

The USPTO published patent application US20260092034A1 for 7-azaindole analogs as serotonin receptor agonists for treating neurological disorders. Assigned to Kuleon LLC with inventor David Gilles, the application covers both hallucinogenic and non-hallucinogenic compounds. The patent application was filed December 8, 2025, under application number 19412382.

Indole Derivatives as Serotonergic Agents for CNS Disorders

USPTO published Application US20260092035A1 disclosing indole derivatives of general Formula (I) as serotonergic agents useful for treating CNS disorders including psychosis and mental illnesses. Inventor Abdelmalik Slassi filed the application on December 9, 2025 (Application No. 19413522). This patent application publication represents a routine intellectual property filing with no compliance obligations or regulatory deadlines for third parties.

Crystalline T-type calcium channel salt patent

The USPTO published patent application US20260092036A1 by inventors Daniel Thomas Walters and Thomas San Ie on April 2, 2026. The application discloses Pattern D, a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1), along with pharmaceutical compositions and methods for treating neurological and psychiatric disorders. The application was originally filed on August 27, 2025, with application number 19311030.